Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$65.29
+0.1%
$63.90
$52.50
$77.00
$1.41B0.57313,678 shs98,504 shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.78
+5.9%
$2.22
$0.82
$4.08
$384.43M1.48971,729 shs794,726 shs
89BIO stock logo
ETNB
89BIO
$10.14
+0.4%
$9.26
$4.16
$11.84
$1.48B1.281.52 million shs1.94 million shs
Mesoblast Limited stock logo
MESO
Mesoblast
$10.79
-0.6%
$11.30
$5.78
$22.00
$1.36B2.39277,456 shs208,906 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
0.00%-0.32%+9.04%-3.30%+7.35%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
0.00%+8.40%+17.58%+90.07%+238.41%
89BIO stock logo
ETNB
89BIO
0.00%+2.84%+1.81%+75.74%+35.56%
Mesoblast Limited stock logo
MESO
Mesoblast
0.00%-1.19%-7.06%+2.08%+58.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.7169 of 5 stars
2.51.00.03.32.03.31.3
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.3886 of 5 stars
3.62.00.00.03.35.00.0
89BIO stock logo
ETNB
89BIO
1.9204 of 5 stars
3.51.00.00.02.30.80.6
Mesoblast Limited stock logo
MESO
Mesoblast
2.3722 of 5 stars
3.51.00.00.03.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$80.1322.72% Upside
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.10
Buy$12.67356.46% Upside
89BIO stock logo
ETNB
89BIO
3.00
Buy$26.43160.64% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
3.00
Buy$18.0066.82% Upside

Current Analyst Ratings Breakdown

Latest CMPX, ETNB, ANIP, and MESO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform$9.00
6/27/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
6/11/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/12/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$86.00 ➝ $86.00
5/10/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/9/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
4/30/2025
89BIO stock logo
ETNB
89BIO
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/24/2025
89BIO stock logo
ETNB
89BIO
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
4/22/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$614.38M2.30$7.60 per share8.59$19.11 per share3.42
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K451.44N/AN/A$0.91 per share3.05
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/A$3.34 per shareN/A
Mesoblast Limited stock logo
MESO
Mesoblast
$5.67M243.16N/AN/A$4.21 per share2.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$1.27N/A15.51N/A-3.12%21.35%7.52%8/5/2025 (Estimated)
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)
89BIO stock logo
ETNB
89BIO
-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)

Latest CMPX, ETNB, ANIP, and MESO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.37$1.70+$0.33$0.69$179.75 million$197.12 million
5/8/2025Q1 2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
5/1/2025Q1 2025
89BIO stock logo
ETNB
89BIO
-$0.50-$0.49+$0.01-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
89BIO stock logo
ETNB
89BIO
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.46
2.66
1.98
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
8.33
8.33
89BIO stock logo
ETNB
89BIO
0.06
18.03
18.03
Mesoblast Limited stock logo
MESO
Mesoblast
0.22
0.96
0.63

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
89BIO stock logo
ETNB
89BIO
N/A
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
11.10%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
29.80%
89BIO stock logo
ETNB
89BIO
2.60%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.66 million19.26 millionOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20138.28 million97.08 millionNot Optionable
89BIO stock logo
ETNB
89BIO
40145.98 million142.19 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
80127.78 million103.76 millionOptionable

Recent News About These Companies

Mesoblast Shares Surge on FDA Alignment
Mesoblast Limited (MSB.AX)
Which S&P 500 Move Matters?

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$65.29 +0.07 (+0.11%)
As of 07/3/2025 01:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.78 +0.16 (+5.92%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$2.78 0.00 (0.00%)
As of 07/3/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

89BIO stock logo

89BIO NASDAQ:ETNB

$10.14 +0.04 (+0.40%)
Closing price 07/3/2025 02:41 PM Eastern
Extended Trading
$10.14 -0.01 (-0.05%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$10.79 -0.07 (-0.64%)
Closing price 07/3/2025 03:26 PM Eastern
Extended Trading
$10.79 0.00 (0.00%)
As of 07/3/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.